The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative.
Cardiovascular disease
Lifelines
Primary prevention
Risk assessment
Risk factors
Journal
International Journal of Cardiology. Hypertension
ISSN: 2590-0862
Titre abrégé: Int J Cardiol Hypertens
Pays: Netherlands
ID NLM: 101773659
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
02
06
2020
revised:
10
07
2020
accepted:
15
07
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
It is unknown whether population based single assessment of cardiovascular disease (CVD) risk and feedback to individuals and general practitioners results in initiation of preventive cardiovascular pharmacotherapy in those at risk. The population based cohort study Lifelines was linked to the IADB.nl pharmacy database to assess information on the initiation of preventive medication ( Before the Lifelines baseline visit, 34% (out of 1,527, 95% Confidence interval (CI) 32%-36%) and 30% (out of 1,991, 95%CI 28%-32%) of the individuals at risk had a blood pressure or lipid lowering drug prescription, respectively. In those at risk, the use of blood pressure lowering medication, increased substantially during the year of the baseline visit. Treating individuals at increased risk (≥5% 10-year risk) with lipid or blood pressure lowering medication ( Primary prevention of CVD in the general population appears suboptimal. Feedback of cardiovascular risk factors resulted in a substantial increase of blood pressure lowering medication and extrapolated health benefits.
Sections du résumé
BACKGROUND
BACKGROUND
It is unknown whether population based single assessment of cardiovascular disease (CVD) risk and feedback to individuals and general practitioners results in initiation of preventive cardiovascular pharmacotherapy in those at risk.
METHODS
METHODS
The population based cohort study Lifelines was linked to the IADB.nl pharmacy database to assess information on the initiation of preventive medication (
RESULTS
RESULTS
Before the Lifelines baseline visit, 34% (out of 1,527, 95% Confidence interval (CI) 32%-36%) and 30% (out of 1,991, 95%CI 28%-32%) of the individuals at risk had a blood pressure or lipid lowering drug prescription, respectively. In those at risk, the use of blood pressure lowering medication, increased substantially during the year of the baseline visit. Treating individuals at increased risk (≥5% 10-year risk) with lipid or blood pressure lowering medication (
CONCLUSION
CONCLUSIONS
Primary prevention of CVD in the general population appears suboptimal. Feedback of cardiovascular risk factors resulted in a substantial increase of blood pressure lowering medication and extrapolated health benefits.
Identifiants
pubmed: 33447768
doi: 10.1016/j.ijchy.2020.100042
pii: S2590-0862(20)30019-7
pmc: PMC7803074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100042Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
G Ital Cardiol (Rome). 2017 Jul-Aug;18(7):547-612
pubmed: 28714997
Cochrane Database Syst Rev. 2016 Jan 29;(1):CD010411
pubmed: 26824223
BMJ Open. 2013 Aug 30;3(8):e003423
pubmed: 23996822
Lancet. 2019 Feb 2;393(10170):407-415
pubmed: 30712900
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
J Health Serv Res Policy. 1999 Apr;4(2):96-100
pubmed: 10387413
Heart. 2016 Jan;102(1):63-8
pubmed: 26261158
Lancet. 2014 Aug 16;384(9943):591-598
pubmed: 25131978
J Hypertens. 2014 Dec;32(12):2285-95
pubmed: 25255397
Int J Epidemiol. 2016 Aug;45(4):1236-1246
pubmed: 27170762
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):285-92
pubmed: 23763527
Ann Fam Med. 2017 Jan;15(1):23-36
pubmed: 28376458
Clin Epidemiol. 2018 Aug 16;10:981-989
pubmed: 30147377
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Nat Rev Cardiol. 2019 Jul;16(7):387-388
pubmed: 31110263
Int J Cardiol. 2017 Feb 1;228:495-500
pubmed: 27875724
Diabetologia. 2017 Nov;60(11):2183-2191
pubmed: 28831535
Int J Epidemiol. 2005 Feb;34(1):181-92
pubmed: 15333620
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Int J Epidemiol. 2015 Aug;44(4):1172-80
pubmed: 25502107